The pre-clinical evidence for NLRP3 in COVID-19, the correlation with outputs from NLRP3 and disease severity, the partial success of anakinra in trials, and a marginal benefit provided by the NLRP3 inhibitor indicate that further studies are warranted into the targeting of NLRP3, most likely in stratified trials, to limit the damaging effects of inflammation occurring during COVID-19. This evidence concerns the gene NLRP3 and COVID-19.